News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment side-effects news

Show

From To
Hepatitis C treatment
French studies report real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection

Adding boceprevir or telaprevir to interferon-based therapy showed promising indications of efficacy and acceptable safety for difficult-to-treat HIV/HCV co-infected prior non-responders in a pair of French studies presented

Published
05 March 2013
By
Liz Highleyman
Hepatitis C treatment side-effects
Health Canada Warns Of Serious Skin Reactions From Hepatitis C Drug

Two months after the FDA issued a safety alert informing about the serious skin reactions, some fatal, in patients taking Vertex Pharmaceuticals Inc.'s (VRTX: Quote) hepatitis C drug Incivek (telaprevir), it is now health Canada's turn to alert health-care providers and patients.

Published
01 March 2013
From
RTT News
Hepatitis C treatment
Hepatitis C Model Delivers Great Care Anywhere

Optimal HCV treatment for patients in a comprehensive health system requires an efficient and effective process. Ideally, the established structure would support rural as well as urban settings and allow for sharing of information, education of providers, and metrics to monitor treatments. Such a process was established successfully within the Department of VA.

Published
25 February 2013
From
Infectious Disease Special Edition
Hepatitis C treatment side-effects
Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

Published
15 February 2013
From
CATIE
New and experimental hepatitis C treatment
Hepatitis C progress in pipeline: New drugs to treat virus expected be available in 2014-15

For more on this rapidly changing landscape, we turned to Dr. Donald M. Jensen, director of the Center for Liver Diseases at University of Chicago Medicine and a noted hepatitis C researcher, with more than 100 peer-reviewed articles.

Published
29 January 2013
From
Chicago Tribune
Hepatitis C treatment side-effects
Small UK study suggests that depression does not have an impact on hepatitis C treatment outcomes in people co-infected with HIV

Depression does not influence hepatitis C treatment outcomes in people co-infected with HIV, according to the results of a small study conducted in Brighton and presented to

Published
04 January 2013
By
Michael Carter
Hepatitis C treatment side-effects
Vertex hepatitis C drug Incivek gets 'black box' warning over possible fatal skin conditions

The FDA says patients taking the pill in combination with two other treatments should stop immediately if they develop a rash that grows worse or comes with symptoms like a fever, diarrhea or mouth sores.

Published
20 December 2012
From
Washington Post
Hepatitis C treatment
Adherence to hepatitis C treatment: unravelling the complexities

Successful adherence to hepatitis C treatment may require physicians and care teams to address a wide range of factors, according to research from the United States and Germany

Published
13 December 2012
By
Rob Camp
Side-effects
Liver toxicity uncommon with modern antiretroviral drugs, but higher risk for HIV/HCV coinfected

Recently approved antiretroviral drugs are generally well-tolerated and seldom cause serious liver enzyme elevations, although protease inhibitors are somewhat more likely to do so, researchers reported in the November 28, 2012, advance online edition of AIDS. People with HIV/HCV coinfection are more likely to experience liver toxicity, however.

Published
06 December 2012
From
HIVandHepatitis.com
New and experimental hepatitis C treatment
Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring

Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis)

Published
05 December 2012
By
Liz Highleyman
← First123Next →

Filter by country